In esophageal and stomach cancers ... have too much of a protein called human epidermal growth factor receptor 2 (HER2). People with HER2-positive cancer can benefit from a HER2-directed medication ...

Detailed price information for Prophase Labs Inc (PRPH-Q) from The Globe and Mail including charting and trades.

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Newport Beach, Calif.-based Hoag became the first hospital in the U.S. to offer EsoGuard testing. The test is used by physicians to detect precancerous DNA changes in esophageal cells, helping to ...

Esophageal adenocarcinoma (EAC), one of two major forms of esophageal cancer, is the sixth most deadly cancer worldwide for which no effective targeted therapy exists. Patients need to rely on ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Esophageal cancer, illustration. Barrett’s esophagus affects the lining of the esophagus and increases the risk of developing esophageal adenocarcinoma, a serious and often deadly cancer.

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change ...

Esophageal adenocarcinoma (EAC), one of two major forms of esophageal cancer, is the sixth most deadly cancer worldwide for which no effective targeted therapy exists.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Learn about the "pill-on-a-thread" that could replace endoscopies for half of all patients at risk of developing esophageal cancer.

Upper GI cancer treatment depends on a number of factors, and may include treatments such as surgery, chemotherapy, radiation ...